1-20 of 20
Nicole Huebener
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 5469: ITCC-P4, a preclinical proof-of-concept drug testing platform as a tool for pharmacological screening in pediatric tumor models

Free
Emilie Indersie, Sophie Branchereau, Brice Fresneau, Christophe Chardot, Didier Surdez, Alexandra Saint-Charles, Maria Eugénia Marques da Costa, Ángel M. Carcaboso, Katia Scotlandi, Massimo Moro, Heinrich Kovar, Jan-Henning Klusmann, Klaus-Michael Debatin, Simon Bomken, Louis Chesler, Chris Jones, Beat Schäfer, Marco Wachtel, Johannes Gojo, Walter Berger, Christina Guttke, Maureen Hattersley, Frédéric Colland, Ashley Strougo, Dennis Gürgen, Jens Hoffmann, Julia Schueler, Pablo M. Aviles, María José Guillén, Aniello Federico, Apurva Gopisetty, Justyna Anna Wierzbinska, Andreas Schlicker, Sara Colombetti, Olaf Heidenreich, Fatima Iradier, Nicole Huebener, Natalie Jäger, Jan Koster, Marcel Kool, Gudrun Schleiermacher, Jan J. Molenaar, Birgit Geoerger, David J. Shields, Hubert N. Caron, Louis F. Stancato, Stefan M. Pfister, Gilles Vassal, Eva-Maria Rief, Olivier Déas
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 5469.
https://doi.org/10.1158/1538-7445.AM2024-5469
Published: 22 March 2024
View articletitled, Abstract 5469: ITCC-P4, a preclinical proof-of-concept drug testing platform as a tool for pharmacological screening in pediatric tumor models
Journal Articles

Abstract 3571: The ITCC-P4 sustainable platform of fully characterized PDXs supports the preclinical proof-of-concept drug testing of high-risk pediatric tumor models

Free
Aniello Federico, Apurva Gopisetty, Didier Surdez, Yasmine Iddir, Alexandra Saint-Charles, Justyna Wierzbinska, Andreas Schlicker, Richard Volckmann, Danny Zwijnenburg, Sara Colombetti, Olaf Heidenreich, Fatima Iradier, Heinrich Kovar, Jan-Henning Klusmann, Klaus-Michael Debatin, Simon Bomken, Christina Guttke, Maureen M. Hattersley, Frédéric Colland, Ashley Strougo, María José Guillén, Louis Chesler, Chris Jones, Maria Eugénia Marques da Costa, Katia Scotlandi, Massimo Moro, Beat Schäfer, Marco Wachtel, Johannes Gojo, Walter Berger, Ángel Montero Carcaboso, Dennis Gürgen, Jens Hoffmann, Emilie Indersie, Stefano Cairo, Julia Schueler, Nicole Huebener, Johannes H. Schulte, Jan J. Molenaar, Birgit Geoerger, David J. Shields, Hubert N. Caron, Gilles Vassal, Lou F. Stancato, Lou F. Stancato, Stefan M. Pfister, Natalie Jäger, Jan Koster, Marcel Kool, Gudrun Schleiermacher
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3571.
https://doi.org/10.1158/1538-7445.AM2023-3571
Published: 04 April 2023
View articletitled, Abstract 3571: The ITCC-P4 sustainable platform of fully characterized PDXs supports the preclinical proof-of-concept drug testing of high-risk pediatric tumor models
Journal Articles

Abstract 2808: GD2-specific genetically engineered NK cell therapy is effective in a drug-resistant neuroblastoma xenograft mouse model

Free
Diana Seidel, Anastasia Shibina, C. Patrick Reynolds, Winfried S. Wels, Nicole Huebener, Holger N. Lode
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 2808.
https://doi.org/10.1158/1538-7445.AM2014-2808
Published: 01 October 2014
View articletitled, Abstract 2808: GD2-specific genetically engineered NK cell therapy is effective in a drug-resistant neuroblastoma xenograft mouse model
Journal Articles

Abstract A28: Generation and characterization of anti-idiotype antibody ganglidiomab as GD2 surrogate for immunotherapy of neuroblastoma.

Free
Holger N. Lode, Manuela Schmidt, Diana Seidel, Nicole Huebener, Diana Brackrock, Matthias Bleeke, Daniel Reker, Sven Brandt, Hans-Peter Mueller, Christiane Helm, Nikolai Siebert
Journal: Cancer Research
Cancer Res (2013) 73 (1_Supplement): A28.
https://doi.org/10.1158/1538-7445.TUMIMM2012-A28
Published: 02 April 2014
View articletitled, Abstract A28: Generation and characterization of anti-idiotype antibody ganglidiomab as GD2 surrogate for immunotherapy of neuroblastoma.
Journal Articles

Abstract 1808: Neuroblastoma cell lines established from progressive disease that exhibit partial or multi drug resistance are highly sensitive to chimeric receptor scFv(ch14.18)-zeta mediated NK cell killing

Free
Diana Seidel, Anastasia Shibina, C. Patrick Reynolds, Winfried S. Wels, Holger N. Lode, Nicole Huebener
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 1808.
https://doi.org/10.1158/1538-7445.AM2011-1808
Published: 15 April 2011
View articletitled, Abstract 1808: Neuroblastoma cell lines established from progressive disease that exhibit partial or multi drug resistance are highly sensitive to chimeric receptor scFv(ch14.18)-zeta mediated NK cell killing
Journal Articles

Abstract LB-155: A new syngeneic MYCN-overexpressing neuroblastoma mouse model and MYCN-DNA vaccine

Free
Alexander Stermann, Nicole Huebener, Holger N. Lode
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): LB-155.
https://doi.org/10.1158/1538-7445.AM2011-LB-155
Published: 15 April 2011
View articletitled, Abstract LB-155: A new syngeneic MYCN-overexpressing neuroblastoma mouse model and MYCN-DNA vaccine
Journal Articles

Abstract 1800: 4-HPR (fenretinide) sensitizes human neuroblastoma cells for antibody-independent and ch14.18-mediated NK cell killing

Free
Anastasia Shibina, Diana Seidel, Srinivas Somanchi, Holger N. Lode, Dean A. Lee, C.Patrick Reynolds, Nicole Huebener
Journal: Cancer Research
Cancer Res (2011) 71 (8_Supplement): 1800.
https://doi.org/10.1158/1538-7445.AM2011-1800
Published: 15 April 2011
View articletitled, Abstract 1800: 4-HPR (fenretinide) sensitizes human neuroblastoma cells for antibody-independent and ch14.18-mediated NK cell killing
Journal Articles

Abstract 5601: NK cells engineered to express the chimeric receptor scFv(ch14.18)-zeta specifically lyse GD2 expressing neuroectodermal tumors

Free
Diana Seidel, Nicole Huebener, Tina Mueller, Dörthe Pferdmenges, Anastasia Shibina, Torsten Tonn, Ulrike Koehl, Ruth Esser, Winfried S. Wels, Holger N. Lode
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 5601.
https://doi.org/10.1158/1538-7445.AM10-5601
Published: 15 April 2010
View articletitled, Abstract 5601: NK cells engineered to express the chimeric receptor scFv(ch14.18)-zeta specifically lyse GD2 expressing neuroectodermal tumors
Journal Articles

Abstract 4758: A new syngeneic MYCN-overexpressing neuroblastoma mouse model and MYCN-DNA vaccine

Free
Alexander Stermann, Nicole Huebener, Diana Seidel, Anastasia Shibina, Stefan Fest, Gerhard Gaedicke, Holger N. Lode
Journal: Cancer Research
Cancer Res (2010) 70 (8_Supplement): 4758.
https://doi.org/10.1158/1538-7445.AM10-4758
Published: 15 April 2010
View articletitled, Abstract 4758: A new syngeneic MYCN-overexpressing neuroblastoma mouse model and MYCN-DNA vaccine
Journal Articles

The development of a new murine MYCN-amplified neuroblastoma cell line

Free
Alexander Stermann, Nicole Huebener, Stefan Fest, Anja Wohler, Bianca Baykan, Gerhard Geadicke, Holger Lode
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 1020.
Published: 01 May 2008
View articletitled, The development of a new murine MYCN-amplified neuroblastoma cell line
Journal Articles

A novel legumain DNA vaccine effectively eradicates neuroblastoma and induces long-term survival in vivo

Free
Anja Woehler, Nicole Huebener, Stefan Fest, Alexander Stermann, Gerhard Gaedicke, Holger N Lode
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 2868.
Published: 01 May 2008
View articletitled, A novel legumain DNA vaccine effectively eradicates neuroblastoma and induces long-term survival in vivo
Journal Articles

Survivin minigene DNA vaccination induces an effective CD8+ T cell response against neuroblastoma

Free
Stefan Fest, Nicole Huebener, Matthias Bleeke, Tahir Durmus, Alexander Stermann, Ana Zenclussen, Elke Michalsky, Ines Jaeger, Gerhard Gaedicke, Ralph Reisfeld, Holger Lode
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 2867.
Published: 01 May 2008
View articletitled, Survivin minigene DNA vaccination induces an effective CD8+ T cell response against neuroblastoma
Journal Articles

Xenogeneic immunization with a human tyrosine hydroxylase DNA vaccine effectively eradicates established neuroblastoma and induces long lasting protective immunity in mice

Free
Nicole Huebener, Stefan Fest, Anja Woehler, Alexander Stermann, Bianca Baykan, Gerhard Gaedicke, Holger Lode
Journal: Cancer Research
Cancer Res (2008) 68 (9_Supplement): 5297.
Published: 01 May 2008
View articletitled, Xenogeneic immunization with a human tyrosine hydroxylase DNA vaccine effectively eradicates established neuroblastoma and induces long lasting protective immunity in mice
Journal Articles

Xenogeneic immunization with a human tyrosine hydroxylase DNA vaccine is effective against neuroblastoma in vivo

Free
Nicole Huebener, Stefan Fest, Kerstin Hilt, Yan Zeng, Silke Weixler, Gerhard Gaedicke, Holger Lode
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 1887.
Published: 01 May 2007
View articletitled, Xenogeneic immunization with a human tyrosine hydroxylase DNA vaccine is effective against neuroblastoma in vivo
Journal Articles

Fractalkine (CX3CL1) rich neuroblastoma microenvironments favor T-cell mediated eradication of metastases following targeted IL-2 immuncytokine therapy

Free
Holger Lode, Yan Zeng, Nicole Huebener, Stefan Fest, Ulrike Schroeder, Silke Weixler, Alexander Schramm, Angelika Eggert, Gerhard Gaedicke
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 517.
Published: 01 May 2007
View articletitled, Fractalkine (CX3CL1) rich neuroblastoma microenvironments favor T-cell mediated eradication of metastases following targeted IL-2 immuncytokine therapy
Journal Articles

Survivin minigene DNA vaccine is effective against neuroblastoma

Free
Stefan Fest, Nicole Huebener, Matthias Bleeke, Alexander Stermann, Silke Weixler, Gerhard Gaedicke, Rong Xiang, Ralph Reisfeld, Holger Lode
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 1875.
Published: 01 May 2007
View articletitled, Survivin minigene DNA vaccine is effective against neuroblastoma
Journal Articles

Mimotope optimization for GD2 directed anti-neuroblastoma immunotherapy

Free
Matthias Bleeke, Stefan Fest, Nicole Huebener, Christiane Landgraf, Rudolf Volkmer, Gerhard Gaedicke, Elke Michalsky, Ines Jaeger, Robert Preissner, Holger Lode
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 5101.
Published: 01 May 2007
View articletitled, Mimotope optimization for GD2 directed anti-neuroblastoma immunotherapy
Journal Articles

Fractalkine (CX3CL1)– and Interleukin-2–Enriched Neuroblastoma Microenvironment Induces Eradication of Metastases Mediated by T Cells and Natural Killer Cells

Free
Yan Zeng, Nicole Huebener, Stefan Fest, Silke Weixler, Ulrike Schroeder, Gerhard Gaedicke, Rong Xiang, Alexander Schramm, Angelika Eggert, Ralph A. Reisfeld, Holger N. Lode
Journal: Cancer Research
Cancer Res (2007) 67 (5): 2331–2338.
https://doi.org/10.1158/0008-5472.CAN-06-3041
Published: 01 March 2007
View articletitled, Fractalkine (CX3CL1)– and Interleukin-2–Enriched Neuroblastoma Microenvironment Induces Eradication of Metastases Mediated by T Cells and Natural Killer Cells
Open the PDF for Fractalkine (CX3CL1)– and Interleukin-2–Enriched Neuroblastoma Microenvironment Induces Eradication of Metastases Mediated by T Cells and Natural Killer Cells in another window
Journal Articles

Characterization of GD2 Peptide Mimotope DNA Vaccines Effective against Spontaneous Neuroblastoma Metastases

Free
Stefan Fest, Nicole Huebener, Silke Weixler, Matthias Bleeke, Yan Zeng, Anne Strandsby, Rudolf Volkmer-Engert, Christiane Landgraf, Gerhard Gaedicke, Angelika B. Riemer, Elke Michalsky, Ines S. Jaeger, Robert Preissner, Elisabeth Förster-Wald, Erika Jensen-Jarolim, Holger N. Lode
Journal: Cancer Research
Cancer Res (2006) 66 (21): 10567–10575.
https://doi.org/10.1158/0008-5472.CAN-06-1158
Published: 01 November 2006
View articletitled, Characterization of GD2 Peptide Mimotope DNA Vaccines Effective against Spontaneous Neuroblastoma Metastases
Open the PDF for Characterization of GD2 Peptide Mimotope DNA Vaccines Effective against Spontaneous Neuroblastoma Metastases in another window
Journal Articles

Peptide mutation analysis results in potent GD2 mimotope peptides for DNA vaccination against neuroblastoma

Free
Holger N. Lode, Mathias Bleeke, Stefan Fest, Nicole Huebener, Yan Zeng, Silke Weixler, Rudolf Volkmer, Elisabeth Förster-Waldl, Erika Jensen-Jarolim, Gerhard Gaedicke
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 332.
Published: 15 April 2006
View articletitled, Peptide mutation analysis results in potent GD2 mimotope peptides for DNA vaccination against neuroblastoma